Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Paris, France - Online CME

Video navigation menu

Residual CV risk and TG 0:34
Trials with omega-3 FAs 2:02
Icosapent ethyl and generalizability of REDUCE-IT 4:56
Additional observations with high dose EPA 6:30
Conclusions 8:12

Educational information

This lecture by prof. Gabriel Steg was part of an accredited symposium "Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides" held during the virtual ESC Congress 2021.

Faculty

Gabriel Steg is professor at the Department of Cardiology in the Hôpital Bichat, Paris, France.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant received from Amarin.

Click here for the meeting report View slides of this presentation

Online-CME

This is available as accredited online CME on coursepath for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.